Skip to content

Vibrations to treat rheumatism

Evaluation of the effect of mechanical vibrations generated on oscillating / vibratory platform in patients with systemic lupus erythematosus and bone mass impairment

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-2b4bzq
Enrollment
Unknown
Registered
2017-08-17
Start date
2015-09-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic lupus erythematosus Osteoporosis

Interventions

Participantes: 25 in each group of intervention 4 groups of female gender patients: Lupus, Lupus with osteoporosis, Osteoporosis and healthy controls 2 forms of intervention: Groups WBV and isometry w
Gusi et al., 2006
Zepetnek, 2009)
With the frequency of 25 Hz with 2 mm of amplitude (low amplitude) being increased with progressive increases until the end of the weeks. The individuals will be positioned standing on the base of the
being observed by the researcher throughout the working time. The electronic parameter display will remain covered. The total work will be 14.5 minutes in which the patient will undergo 60 second cycl
The POV will remain off, with the electronic display of the parameters covered, in cycles identical to those of the EVCI. There will be the warm-up of 2 minutes.
Device

Sponsors

Universidade do Estado do Rio de Janeiro
Lead Sponsor
Laboratório de Vibrações Mecânicas e Práticas integrativas e complementares - UERJ
Collaborator

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Signature of the Informed Consent Term; patients older than 40 years and female; followed up at HUPE; lupus diagnosed for at least 6 months (ACR criteria 1997, Hochberg, 1997); use of glucocorticoids for 3 years or more; patients with blood pressure (BP) equal to or greater than 100 x 70 mmHg

Exclusion criteria

Exclusion criteria: Presence of neurological / e or psychiatric disease that causes fear to the movements on the oscillating / vibratory platform; severe or incapacitating clinical illness; at the discretion of the investigator; Previous history of low-impact fracture and or classified as severe osteoporosis; personal history of avascular hip necrosis; active smoking; Alcoholism; use of joint protheses; patients refusing to sign the term Of Consent to participate in the study.

Design outcomes

Primary

MeasureTime frame
Increase in muscle activation at weeks 6 and 12 for WBV intervention obtained through surface electromyography (muscles - vastus lateralis, medial gastrocnemius and anterior tibialis of the lower right limb), with a variation of at least 5%.;Increase in handgrip strenght at weeks 6 and 12 for WBV intervention obtained through handgrip dynamometry, with a variation of at least 5%

Secondary

MeasureTime frame
Reductions in the measures of fatigue; at weeks 6 and 12 for WBV intervention using the FACIT-Fatigue scale of 13 items;with a variation of at least 5%.;Increase in the measures of fatigue; at weeks 6 and 12 for WBV intervention using the SF-36 questionnaire;with a variation of at least 5%.;Alterations in the measures of functionality; at weeks 6 and 12 for WBV intervention using the Health Assessment Questionnaire (HAQ) questionnaire in Portuguese;with a variation of at least 5%.;Reductions in the measures of falls risk; at weeks 6 and 12 for WBV intervention using the Timed Up and Go (TUG) test and the FES-I-Brazil questionnaire;with a variation of at least 5%.

Countries

Brazil

Contacts

Public ContactCarla Dionello

Universidade do Estado do Rio de Janeiro

carla_dionello@yahoo.com.br+55(21)28688332

Outcome results

None listed

Source: REBEC (via WHO ICTRP)